Clinical Trials Browser

Enrolling by invitation × INDUSTRY × 30 days × Clear all

Myasthenia Gravis

NCT06540144 2026-04-13

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

12 enrolled

Myasthenia Gravis

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Phase 1 Enrolling by invitation

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06940648 2026-04-13

VIABLE

Phase NA Enrolling by invitation

30 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07296263 2026-04-13

Contrast PMR

Phase NA Enrolling by invitation

85 enrolled

Infections

NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Enrolling by invitation

500 enrolled

Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

NCT07503613 2026-04-06

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Enrolling by invitation

100 enrolled

CNS

Neuroma, Acoustic, Hearing Loss

NCT06506955 2026-04-03

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05303532 2026-03-24

ROSY-D

Phase 3 Enrolling by invitation

214 enrolled

Tumor-Agnostic

Neoplasms

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Phase 1/2 Enrolling by invitation

30 enrolled

CNS

Adenoviridae Infections, Glioma

NCT07126990 2026-03-23

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

Phase 1/2 Enrolling by invitation

40 enrolled

CNS

Glioma

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Enrolling by invitation

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07226180 2026-03-18

Development and Application of Patient-Derived Models of Cancer

Enrolling by invitation

40 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

ziMyG+

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

VIABLE

Contrast PMR

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

ROSY-D

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Development and Application of Patient-Derived Models of Cancer